Eli Lilly’s (LLY) Growth Story Keeps Adding Chapters

Eli Lilly's growth story continues to expand as the company announced strong Q2 results and secured regulatory approvals. On August 5, Lilly reported a 48% revenue increase, followed by a UK regulatory greenlight for its oral GLP-1 drug, Foundayo, for weight management and type 2 diabetes. Foundayo became the first European market to approve the pill, propelling the stock up nearly 4% on the news. The company now has its sights set on expanding into 40 more countries, with a global rollout expected by 2027.

Lilly's strategy of diversifying its treatment portfolio, rather than relying on a single blockbuster, has proven successful. Zepbound remains its leading injectable, while Foundayo caters to patients who prefer not to use needles. Retatrutide, which showed positive results in three Phase 3 trials, is being targeted towards those requiring more substantial weight loss or dealing with complications like sleep apnea.

Over 80% of Foundayo prescriptions have been given to patients who had never used a GLP-1 drug before, indicating the company's ability to tap into new markets without cannibalizing its existing revenue.

The company's second-quarter revenue rose 48% year-over-year, and adjusted EPS reached $8.38. Management raised full-year revenue guidance to $85 billion to $87 billion. However, the valuation comes with a premium, trading at 32.47 times forward earnings, which is significantly higher than the 18.5 times average for healthcare stocks. This multiple assumes continued growth without any major setbacks.

Lilly's GLP-1 portfolio, comprising Mounjaro and Zepbound, accounts for 65% of Q2 revenue. While volume growth has outpaced the price cuts, which have reduced average realized prices by 13% year-over-year, the company's focus on affordability and market access may require sustained demand sensitivity. Competition is heating up, with Novo Nordisk's oral Wegovy pill and its upcoming CagriSema entering the UK market, and semaglutide's patent protection expiring in India, China, and Brazil, potentially opening the door for generic competitors in growth markets.

Despite a slight reduction in hedge fund ownership from 137 funds to 132, short interest remains low at 1.02% of the float. The stock's forward P/E ratio suggests that investors are willing to pay a growth premium, even as fund positioning has cooled. Eli Lilly has transformed a single weight-loss drug into a multi-product platform, and with regulators clearing new markets for Foundayo and the introduction of more treatments, the company is positioning itself for sustained growth.

However, the high valuation and reliance on two drugs leave the stock vulnerable to competition from rivals and generic alternatives. While there is potential in Eli Lilly, other AI stocks may offer greater upside potential with lower downside risk.